FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Remorseful Regulator Leads Reform Fight
- Lightning Round: AT&T, Verizon, Novartis and More
- Lightning Round OT: Alcoa, Weight Watchers and More
- Why Amazon Rules Retail
- Nordic American: Sinking Ship or Titan Tanker?
- Cramer: What Monday’s Housing Number Really Means
- Cramer: Buy These Banks, If...
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Add ResMed to the list of companies Cramer said could make out big when the newest Medicare bill is passed.
ResMed [RMD
Loading...
()
] makes continuous positive airway pressure devices – sleep-apnea machines, in layman’s terms – and the company controls 40% of the market in a duopoly with Respironics.
ResMed stock had dropped, though, after Medicare’s administrators introduced competitive bidding to bring down the price of sleep-apnea machines. But Cramer said he thought Wall Street overreacted, especially since less than half the company’s sales come from the U.S., and only 20% of that is Medicare-related. There’s also the chance that, while the first round of bidding got underway Tuesday, Washington could delay the second round, due in mid-2009.
The growth catalyst for ResMed is the increased awareness, and as a result increased diagnosis, of sleep apnea. The company estimates that 35 million potential patients aren’t being treated. As doctors realize just how pervasive this disease is, ResMed’s business should pick up.
Another thing that should boost sales at ResMed is that Medicare administrators have made home-diagnostics for sleep apnea a reimbursable treatment. This is a big deal because most sleep-apnea patients are directed to sleep labs, but never go because it’s such a hassle. And since ResMed makes both the sleep-apnea machines and the machines that test for the disease, the company’s in great position to profit now that it looks like more people will be getting tested and treated.
Cramer said ResMed could go as high as $50, a 12-point bump from Tuesday’s close. And even though the takeover rumors pushed the stock up 7% today, Cramer said the growth potential here means the stock is still a buy. Of course, it’s probably a good idea to wait for a pullback, though.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes